Human Interleukin-11

PreclinicalProtein / enzyme

JJun Wang

Human Interleukin-11 is one of 44 small molecule programs targeting Thrombocytopenia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ThrombocytopeniaActive, not recruiting

ThrombocytopeniaPreclinical

Active, not recruiting

Competition

Competitive Landscape

105 competitors in Thrombocytopenia

#DrugCompanyPhaseTrials

Acova

Alnylam Pharmaceuticals

Phase 3

3 2

Plaquenil

Alnylam Pharmaceuticals

Phase 3

2 3

Fabhalta

Cyklokapron

3 5

Prograf

VVeloxis Pharmaceuticals

Phase 3

2 6

Dacogen

Sun Pharma

Phase 3

1 7

Imuran

LLegacy Health System

Phase 3

1 8

Cytoxan

BBaxter Healthcare Corporation

Phase 3

1 9

Xarelto

WWim Janssens

Phase 3

1 10

Best Available Therapy

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Thrombocytopenia

NCT07185893

Clinical

Trials by Indication[1]

Thrombocytopenia1 trial

A Multicenter, Open-label, Randomized Controlled Trial Evaluating the Efficacy and Safety of Romiplostim N01 in the Treatment of Thrombocytopenia Associated With Concurrent/Sequential Chemoradiotherapy and Chemotherapy Combined With/Without Immunotherapy in Solid Tumors

Not yet recruiting·JJun Wang·N/A·NCT07185893·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Human Interleukin-11. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Human Interleukin-11 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Human Interleukin-11. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jun Wang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: JJun Wang

Human Interleukin-11

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News